Skip to main content

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.

Publication ,  Journal Article
Ransom, CE; Huo, Y; Patel, K; Scott, GB; Watts, HD; Williams, P; Siberry, GK; Livingston, EG ...
Published in: J Acquir Immune Defic Syndr
December 1, 2013

OBJECTIVE: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth. METHODS: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ test, and multivariable linear and logistic regression models, including demographic and maternal characteristics. RESULTS: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth. CONCLUSIONS: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.

Duke Scholars

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

December 1, 2013

Volume

64

Issue

4

Start / End Page

374 / 381

Location

United States

Related Subject Headings

  • Weight Gain
  • Virology
  • Tenofovir
  • Pregnancy Complications, Infectious
  • Pregnancy
  • Organophosphonates
  • Infant
  • Humans
  • Female
  • Child Development
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ransom, C. E., Huo, Y., Patel, K., Scott, G. B., Watts, H. D., Williams, P., … P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group, . (2013). Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr, 64(4), 374–381. https://doi.org/10.1097/QAI.0b013e3182a7adb2
Ransom, Carla E., Yanling Huo, Kunjal Patel, Gwendolyn B. Scott, Heather D. Watts, Paige Williams, George K. Siberry, Elizabeth G. Livingston, and Elizabeth G. P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. “Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.J Acquir Immune Defic Syndr 64, no. 4 (December 1, 2013): 374–81. https://doi.org/10.1097/QAI.0b013e3182a7adb2.
Ransom CE, Huo Y, Patel K, Scott GB, Watts HD, Williams P, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374–81.
Ransom, Carla E., et al. “Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.J Acquir Immune Defic Syndr, vol. 64, no. 4, Dec. 2013, pp. 374–81. Pubmed, doi:10.1097/QAI.0b013e3182a7adb2.
Ransom CE, Huo Y, Patel K, Scott GB, Watts HD, Williams P, Siberry GK, Livingston EG, P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374–381.

Published In

J Acquir Immune Defic Syndr

DOI

EISSN

1944-7884

Publication Date

December 1, 2013

Volume

64

Issue

4

Start / End Page

374 / 381

Location

United States

Related Subject Headings

  • Weight Gain
  • Virology
  • Tenofovir
  • Pregnancy Complications, Infectious
  • Pregnancy
  • Organophosphonates
  • Infant
  • Humans
  • Female
  • Child Development